Lumenis Pulse™ 120H Holmium Laser System with MOSES™ 2.0 Technology

Benign prostatic hyperplasia (BPH)

MOSES 2.0 Technology gives you the flexibility to treat patients with a broad range of prostate sizes and is proven to reduce procedure time. 

Proven BPH treatment 

Select an optimized soft-tissue treatment pulse modulation to improve enucleation efficiency in BPH. 

HoLEP with MOSES™ Technology has been demonstrated to result in faster enucleation time (68 vs. 80 min, p=0.03) compared to standard holmium.1

Surgeons new to enucleation demonstrated 44% higher procedural efficiency using MOSES 2.0 Technology compared to standard holmium laser enucleation of the prostate (HoLEP).2

Physician in operating room.
Checkmark in a circle icon.

Demonstrated reduction in procedure time  

  • Improving your HoLEP treatment time provides the opportunity to treat more patients, expand your reach, or reclaim your time. 
  • MOSES Technology has been demonstrated to reduce operative time by 25 minutes compared to traditional HoLEP (101 vs. 126 min, p = 0.03)1
Checkmark in a circle icon.

Potentially get patients home sooner 

  • 90% same-day discharge rate has been demonstrated in patients who received BPH treatment with MOSES technology3 
  • 90% success rate has been demonstrated for same-day catheter removal in select patients4
Checkmark in a circle icon.

Treat patients on anticoagulants

With unique pulse modulation that allows for improved hemostasis, MOSES 2.0 Technology lets you treat patients with comorbidities that require anticoagulants.3,4

Checkmark in a circle icon.

Higher vaporization rate and efficiency

Holmium laser vaporization of the prostate (HoLVP)* with MOSES Technology demonstrates 95%** higher ablation efficiency compared to standard HoLVP, potentially translating into time savings in the operating room.5

Interested in learning more about stone and BPH treatment?

Fill out this form, and a Boston Scientific representative will contact you soon. 

 

*HoLAP (ablation) was recognized and used interchangeably with HoLVP (vaporization) in the AUA guidelines through 2011 and the EAU guidelines through 2014.
**BSC Calculations: 0.91±0.54 g/min vs. 1.77±1.41 g/min, P = 0.01 

References:

  1. Kavoussi NL, Nimmagadda N, Robles J, etc. MOSES technology for holmium laser enucleation of the prostate: A prospective double-blind randomized controlled trial. J Urol. 2021;206:104–108. 
  2. Nottingham CU, Large T, Agarwal DK, Rivera ME, Krambeck AE. Comparison of newly optimized Moses technology vs. standard holmium: YAG for endoscopic laser enucleation of the prostate. J Endourol. 2021;35:1393–1399. 
  3. Large T, Nottingham C, Stoughton C, Williams J, Krambeck A. Comparative study of holmium laser enucleation of the prostate with MOSES enabled pulsed laser modulation. Urology. 2020;136:196–201. 
  4. Agarwal DK, Rivera ME, Nottingham CU, Large T, Krambeck AE. Catheter removal on the same day of holmium laser enucleation of the prostate: Outcomes of a pilot study. Urology. 2020;146:225–229. 
  5. Whiles BB, Martin AJ, Brevik A, etc. Utilization of MOSES modulated pulse mode results in improved efficiency in holmium: YAG laser ablation of the prostate. Urology. 2021;149:187–192. 

Rx Only

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.

Boston Scientific acquired the global surgical business of Lumenis Ltd.  Some registered names of products manufactured and sold by Boston Scientific may contain the term “Lumenis.” Lumenis is a registered trademark of Lumenis Be.

All images are the property of Boston Scientific. All trademarks are the property of their respective owners.